Anti-hepatocellular carcinoma activity of the cyclin-dependent kinase inhibitor AT7519 - 17/06/23
Abstract |
Hepatocellular carcinoma (HCC) is one of the most common cancerous tumors and one of the leading causes of death among cancer-related disorders. Chemotherapy is ineffective in HCC patients, and the number of drugs that are in use is limited. Thus, new molecules are needed that could increase the effectiveness of anti-HCC regimens. Here, we show that AT7519, a CDK inhibitor, exerts positive effects on HCC cells: it inhibits proliferation, migration and clonogenicity. Detailed analysis of the transcriptomes of cells treated with this compound indicated that AT7519 affects a substantial portion of genes that are associated with HCC development and progression. Moreover, we showed that the concomitant use of AT7519 with gefitinib or cabozantinib sensitized HCC cells to these drugs. Thus, our research indicates that AT7519 is worth considering in monotherapy for hepatocellular carcinoma patients or in combination with other drugs, e.g., gefitinib or cabozantinib.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | This study assessed the application of AT7519, a multicyclin-dependent kinase inhibitor, in HCC therapy. |
• | AT7519 inhibited the growth, clonogenicity and migration of HCC cells in a cell cycle-independent mechanism. |
• | RNA-seq revealed altered expression of genes involved in HCC development and survival. |
• | AT7519 increased the potency of several anticancer drugs. |
• | AT7519 could be used alone or in a combination therapeutic strategy for HCC treatment. |
Keywords : RORγ, Hepatocellular carcinoma, HCC, Transcriptional regulation, Chemotherapy, AT7519
Plan
Vol 164
Article 115002- août 2023 Retour au numéro
Article précédent
- Zinc oxide nanoparticles induce toxicity in diffuse large B-cell lymphoma cell line U2932 via activating PINK1/Parkin-mediated mitophagy.
- Zonghong Li, Xuewei Yin, Chunyi Lyu, Teng Wang, Wenhao Wang, Jiachen Zhang, Jinxin Wang, Zhenzhen Wang, Chen Han, Ruixue Zhang, Dadong Guo, Ruirong Xu
- β-Cyclodextrins as affordable antivirals to treat coronavirus infection
- Dalia Raïch-Regué, Raquel Tenorio, Isabel Fernández de Castro, Ferran Tarrés-Freixas, Martin Sachse, Daniel Perez-Zsolt, Jordana Muñoz-Basagoiti, Sara Y. Fernández-Sánchez, Marçal Gallemí, Paula Ortega-González, Alberto Fernández-Oliva, José A. Gabaldón, Estrella Nuñez-Delicado, Josefina Casas, Núria Roca, Guillermo Cantero, Mónica Pérez, Carla Usai, Cristina Lorca-Oró, Júlia-Vergara Alert, Joaquim Segalés, Jorge Carrillo, Julià Blanco, Bonaventura Clotet Sala, José P. Cerón-Carrasco, Nuria Izquierdo-Useros, Cristina Risco
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?